Pirfenidone Therapy and Inducers of Cytochrome P450
First Claim
Patent Images
1. A method of administering pirfenidone therapy to a patient in need thereof, wherein the patient is a smoker, comprising discontinuing smoking to avoid an adverse drug reaction and administering a therapeutically effective amount of pirfenidone.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking.
8 Citations
20 Claims
- 1. A method of administering pirfenidone therapy to a patient in need thereof, wherein the patient is a smoker, comprising discontinuing smoking to avoid an adverse drug reaction and administering a therapeutically effective amount of pirfenidone.
- 8. A method of administering pirfenidone therapy to a patient in need thereof comprising administering to the patient a therapeutically effective amount of pirfenidone and avoiding use or administration of a strong inducer of a cytochrome P450 1A2 (CYP1A2) to avoid an adverse drug reaction.
-
13. A method of administering pirfenidone therapy to a patient in need thereof, comprising administering to the patient a therapeutically effective amount of pirfenidone, and one or more of the following:
-
(a) advising the patient that inducers of a cytochrome P450 (CYP) (CYP1A2) should be avoided or discontinued; (b) advising the patient that smoking should be avoided when using pirfenidone due to the potential for smoking to induce CYP1A2 metabolism resulting in decreased exposure to pirfenidone; (c) advising the patient that smoking should be discontinued before treatment with pirfenidone; (d) advising the patient that administration of pirfenidone in patients that smoke results in a 50% decrease in pirfenidone exposure compared to patients that do not smoke; and (e) advising the patient that smoking may result in decreased pirfenidone exposure due to the potential for smoking to induce CYP1A2 metabolism. - View Dependent Claims (14, 15, 16, 17, 18, 19, 20)
-
Specification